Confronting Stage 3 Lung Cancer With Immunotherapy
The May 2018 FDA approval of the immunotherapeutic durvalumab makes it the first treatment approved to reduce the risk of stage 3 lung cancer progressing.
Progress Against Cancer
The May 2018 FDA approval of the immunotherapeutic durvalumab makes it the first treatment approved to reduce the risk of stage 3 lung cancer progressing.
The FDA approved a hormone therapy for treating men with nonmetastatic prostate cancer that has stopped responding to standard hormone therapy.
The FDA expanded the use of a molecularly targeted therapeutic to include the prevention of bone complications in patients with multiple myeloma.
The FDA approved a molecularly targeted therapeutic for treating certain patients who have breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutation.
An American Association for Cancer Research (AACR) Special Conference highlighted the connections between weight and cancer.
Whole-genome sequencing may help identify the patients who are most likely to benefit from certain types of chemotherapy.
Thyroid cancer survivors – especially those diagnosed before age 40 – have elevated risk for several aging-related diseases.
A Q&A with medical oncologist Patricia Ganz on chemotherapy-related nerve damage.
More Americans are beating childhood cancer, but many experience effects later in life such as high blood pressure.
Study: Urban native populations may have decreased survival following invasive prostate and breast cancer. Urban American Indians and Alaskan Natives (AIAN) appear to have lower survival rates following invasive prostate and breast cancer as...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More